Cardiovascular Therapeutics is a renowned Open Access journal, published by WILEY-HINDAWI, that has been at the forefront of advancing knowledge in the field of cardiology and cardiovascular medicine since its establishment. With a strong commitment to disseminating high-quality research, the journal has successfully positioned itself within the Q2 quartile in multiple categories, including Cardiology and Cardiovascular Medicine, Medicine (miscellaneous), and Pharmacology. The journal is indexed in Scopus, achieving impressive rankings, such as #95 out of 387 in Cardiology, and #87 out of 272 in Medical Pharmacology. Situated in the United Kingdom, Cardiovascular Therapeutics embraces an Open Access model since 2019, ensuring that groundbreaking research is accessible to researchers, practitioners, and students across the globe. The journal is dedicated to publishing original research articles, reviews, and clinical studies that contribute to the understanding and treatment of cardiovascular diseases, making it an essential resource for those invested in improving patient outcomes and advancing therapeutic strategies in this vital area of medicine.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, published by Elsevier Science Inc, stands at the forefront of the medical literature dedicated to advancing our understanding of cancer and blood disorders. With its ISSN 1040-8428 and E-ISSN 1879-0461, this prestigious journal boasts an impressive impact factor, reflecting its significance in the fields of Geriatrics, Hematology, and Oncology. Notably, it has achieved the distinction of being ranked in the top quartile (Q1) for these categories as of 2023, with Scopus rankings placing it in the 93rd percentile in Geriatrics and Gerontology, 87th in Oncology, and 85th in Hematology. Since its inception in 1983 and continuing until 2024, the journal serves as a critical resource for researchers, medical professionals, and students alike, aiming to publish high-quality, peer-reviewed articles that facilitate knowledge exchange and promote innovation in clinical practices and therapeutic strategies. While the journal is not open access, it remains widely accessible through various academic institutions, ensuring that vital research findings reach those who need them most.

Journal of Cardiovascular and Thoracic Research is a premier open access journal published by Tabriz University of Medical Sciences & Health Services, focusing on the dynamic fields of cardiology and cardiovascular medicine. With an ISSN of 2008-5117 and E-ISSN 2008-6830, the journal provides a platform for innovative research and advances in cardiovascular and thoracic health, catering to a global audience of researchers, healthcare professionals, and students. Since its inception as an open access publication in 2010, the journal has established itself within the academic community, evidenced by its inclusion in Scopus and its category quartile ranking (Q3) in 2023. Located in Tabriz, Iran, the journal aims to disseminate high-quality studies that contribute to the understanding and treatment of cardiovascular diseases, thus enabling advancements in this critical field of medicine. With a Scopus rank of 248 out of 387 in the category of Cardiology and Cardiovascular Medicine, the Journal of Cardiovascular and Thoracic Research is dedicated to fostering collaboration and dialogue among researchers and practitioners, promoting a deeper understanding of cardiovascular and thoracic health.

Revista Portuguesa de Cardiologia, published by Elsevier España SLU, stands as a pivotal resource in the realm of Cardiology and Cardiovascular Medicine. With its origins tracing back to 1970, this journal has cultivated a robust academic presence, achieving a 2023 Q3 ranking in its category, and currently holding a position of #220 out of 387 on the Scopus rankings, placing it within the 43rd percentile of its field. This open access journal, available since 2011, aims to disseminate high-quality research and insights relevant to contemporary cardiovascular issues. Its commitment to accessibility and knowledge exchange enhances its importance for clinicians, researchers, and students alike, fostering a more informed community in the fight against cardiovascular diseases. Operating from its base in Barcelona, Spain, the journal welcomes contributions that further the understanding and treatment of heart conditions, contributing significantly to the advancement of cardiovascular health.

Expert Review of Anticancer Therapy, published by Taylor & Francis Ltd, is a distinguished journal focusing on the dynamic and ever-evolving field of oncology and pharmacology. Since its inception in 2001, this journal has played a pivotal role in disseminating critical reviews and analyses of novel anticancer therapies, fostering a deeper understanding among researchers and practitioners alike. With an impressive categorization in the 2023 Q2 quartiles for both Oncology and Pharmacology, it ranks #98 out of 272 in Pharmacology and #165 out of 404 in Oncology according to Scopus metrics, placing it well within the upper echelons of academic journals. The journal’s rigorous peer-review process ensures high-quality publications that are integral for advancing cancer research and therapeutic strategies. Although currently not an open access journal, it aims to bridge the gap between scientific discovery and clinical application, making it an essential resource for anyone involved in the fight against cancer.

Cardiovascular Endocrinology & Metabolism is a leading open-access journal dedicated to advancing our understanding of the interconnections between cardiovascular health and endocrine functions. Published by Lippincott Williams & Wilkins, this journal serves as a vital resource for researchers and clinicians alike, providing timely insights into the intricate relationships between metabolic disorders and cardiovascular diseases. With an impressive impact factor and categorized in Q2 for both Cardiology and Cardiovascular Medicine as well as Endocrinology, Diabetes, and Metabolism, it holds a significant position within its respective fields. The journal has been fully open access since its inception in 2012, ensuring that critical research is accessible to a global audience. By fostering innovation and collaboration, Cardiovascular Endocrinology & Metabolism aims to promote better health outcomes and stimulate novel research directions, making it an essential resource for professionals striving to bridge the gaps between these two critical domains.

Molecular and Clinical Oncology is a dynamic journal published by SPANDIDOS PUBL LTD, aimed at advancing the understanding of cancer biology and treatment modalities. With an ISSN of 2049-9450 and an E-ISSN of 2049-9469, the journal serves as a critical platform for researchers and clinicians dedicated to uncovering novel insights in molecular oncology and enhancing clinical practices. As a testament to its growing influence, the journal has achieved a Q3 ranking in Oncology and a Q4 ranking in Cancer Research for the year 2023, reflecting its commitment to publishing high-quality research. Although currently not an Open Access publication, the journal offers crucial subscription options, ensuring comprehensive access to groundbreaking studies and innovations in the field. With converged years spanning 2018 to 2024, the journal is set to continue enriching the academic community with its valuable contributions, ultimately empowering researchers, professionals, and students engaged in the fight against cancer.

HEART FAILURE REVIEWS is a premier academic journal published by Springer, dedicated to the dynamic field of cardiology and cardiovascular medicine. With an impressive Q1 ranking in 2023, the journal stands as a vital resource for researchers, clinicians, and students seeking to stay abreast of the latest developments in heart failure management and research. Covering a broad spectrum of topics, including innovative therapies, epidemiology, and pathophysiology of heart failure, it fosters an environment for interdisciplinary collaboration. The journal is indexed with an ISSN of 1382-4147 and an E-ISSN of 1573-7322, ensuring widespread dissemination of knowledge. Although it does not currently offer open access options, its rigorous peer-review process guarantees high-quality content that contributes significantly to the scientific community. Established in 1996 and running through 2024, HEART FAILURE REVIEWS continues to be a leading platform for advancing understanding and treatment of heart conditions, making it an indispensable resource for all stakeholders in cardiac health.

TEXAS HEART INSTITUTE JOURNAL, published by the renowned Texas Heart Institute, stands as a pivotal resource in the field of cardiology and cardiovascular medicine. With a history spanning over four decades since its establishment in 1982, this journal addresses a wide range of topics within its scope, including clinical studies, innovative treatments, and groundbreaking research in heart health. Despite its Q3 ranking in both Cardiology and Cardiovascular Medicine, the journal is committed to fostering advancement in medical knowledge and practice, providing an essential platform for healthcare professionals and researchers alike. While currently lacking open access, the journal is recognized for its contributions to the field, aiming to illuminate critical healthcare discussions and promote the exchange of ideas. For those interested in staying at the forefront of cardiovascular research, TEXAS HEART INSTITUTE JOURNAL offers invaluable insights and the latest developments shaping the future of heart care.

Clinical Lymphoma Myeloma & Leukemia is a prestigious journal dedicated to the study and treatment of hematologic malignancies, offering a vital platform for researchers and healthcare professionals in the fields of oncology, hematology, and cancer research. Published by CIG MEDIA GROUP, LP, this journal has established itself as a crucial resource since its inception in 2010, with a continuous commitment to disseminating knowledge until at least 2024. With an impact factor that objectively reflects its influence, it is rated in Q3 quartiles in both Cancer Research and Hematology as well as in Oncology as of 2023. Researchers can access a wealth of articles and studies that explore various dimensions of lymphoma, myeloma, and leukemia, thus fostering an environment of collaboration and innovation. Although it currently does not offer full open access, its extensive archive and rigorous peer-review process ensure the publication of high-quality research, making it an essential resource for anyone dedicated to advancing the science and practice of treating blood cancers.